MediciNova, Inc. (MNOV) Stock

Healthcare · Biotechnology · Member of Other US Stocks

MediciNova, Inc. (MNOV) closed at USD 1.47 on 2026-10-14, a change of +21.5 % over the past year, with a market capitalization of USD 71.37M.

MediciNova, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

MediciNova, Inc. key figures

Previous close

USD 1.47 (2026-10-14)

1-year change

+21.5 %

Market cap

USD 71.37M

Enterprise value

USD 46.07M

P/E ratio (trailing)

-6.91

P/E ratio (forward)

-2.82

EPS (trailing)

-0.21

EPS (forward)

-0.52

PEG ratio

n/a

Price to book

1.92

Revenue growth

240.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.41

Employees

6

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for MediciNova, Inc. and compare it with other stocks.